Development asset linked to Chinese Academy of in public FDA and regional records.
pharma · Nasopharyngeal Carcinoma · Hepatocellular Carcinoma
Chinese Academy of
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chinese Academy of drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
China, TAIZHOU, CN HQ
170 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- China, TAIZHOU, CN
- Employees
- 170
- Programs
- 1328
- Drugs
- 711
- Patents
- 335
Chinese Academy of pipeline
Portfolio lens on 200 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Chinese Academy of drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
-
US regulatory status: approved.
-
abatacept
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: T-lymphocyte activation antigen CD80.
- Target
- T-lymphocyte activation antigen CD80
- Mechanism
- T-lymphocyte activation antigen CD80 inhibitor
-
abemaciclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 6 inhibitor
-
abiraterone
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in Chinese Academy of's portfolio. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Steroid 5-alpha-reductase inhibitor
-
abiraterone acetate
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Steroid 17-alpha-hydroxylase/17,20 lyase.
- Target
- Steroid 17-alpha-hydroxylase/17,20 lyase
- Mechanism
- Cytochrome P450 17A1 inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial urease.
- Target
- Bacterial urease
- Mechanism
- Bacterial urease inhibitor
-
US regulatory status: approved. Mechanism: Glutathione precursor.
- Mechanism
- Glutathione precursor
-
US regulatory status: approved. Molecular target: Retinoid receptor.
- Target
- Retinoid receptor
- Mechanism
- Retinoid receptor agonist
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
adefovir dipivoxil
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.
- Target
- DNA polymerase/reverse transcriptase
- Mechanism
- DNA polymerase/reverse transcriptase inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
afatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Mechanism: Epidermal growth factor receptor erbB1 inhibitor.
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved.
-
alectinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Chinese Academy of's portfolio. Mechanism: EML4-ALK.
- Mechanism
- EML4-ALK
-
US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.
- Target
- ALK tyrosine kinase receptor
- Mechanism
- EML4-ALK
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Farnesyl pyrophosphate synthase.
- Target
- Farnesyl pyrophosphate synthase
- Mechanism
- Farnesyl diphosphate synthase inhibitor
-
allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Chinese Academy of's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
allogeneic umbilical cord-derived cd34- cells, non-expanded
Blood and blood forming organs (B05)Blood and blood forming organs (B05) compound in Chinese Academy of's portfolio.
-
Development asset linked to Chinese Academy of in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Molecular target: Tissue-type plasminogen activator.
- Target
- Tissue-type plasminogen activator
- Mechanism
- Tissue-type plasminogen activator exogenous protein
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
amikacin
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in Chinese Academy of's portfolio.
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records. Mechanism: HERG blocker.
- Mechanism
- HERG blocker
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
-
amlodipine
Cardiovascular system (C09)Cardiovascular system (C09) compound in Chinese Academy of's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records. Molecular target: Platelet-derived growth factor receptor beta.
- Target
- Platelet-derived growth factor receptor beta
- Mechanism
- Platelet-derived growth factor receptor beta inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
apomorphine
Genito-urinary system and sex hormones (G04)Genito-urinary system and sex hormones (G04) compound in Chinese Academy of's portfolio. Mechanism: D2-like dopamine receptor agonist.
- Mechanism
- D2-like dopamine receptor agonist
-
Development asset linked to Chinese Academy of in public FDA and regional records. Molecular target: Hemagglutinin.
- Target
- Hemagglutinin
- Mechanism
- Hemagglutinin negative modulator
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records. Mechanism: Norepinephrine transporter inhibitor.
- Mechanism
- Norepinephrine transporter inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
atropine
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
aumolertinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Chinese Academy of's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
autologous glioma tumor cell lysates (inactivated)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Chinese Academy of's portfolio.
-
avapritinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Platelet-derived growth factor receptor alpha.
- Target
- Platelet-derived growth factor receptor alpha
- Mechanism
- Stem cell growth factor receptor inhibitor
-
avatrombopag
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Chinese Academy of's portfolio. Molecular target: Thrombopoietin receptor.
- Target
- Thrombopoietin receptor
- Mechanism
- Thrombopoietin receptor agonist
-
US regulatory status: approved. Molecular target: Thrombopoietin receptor.
- Target
- Thrombopoietin receptor
- Mechanism
- Thrombopoietin receptor agonist
-
US regulatory status: approved.
-
axitinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
- Target
- Vascular endothelial growth factor receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
azacitidine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 3A inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
baricitinib
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tyrosine-protein kinase JAK1.
- Target
- Tyrosine-protein kinase JAK1
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
bedaquiline
Antiinfectives for systemic use (J04)Antiinfectives for systemic use (J04) compound in Chinese Academy of's portfolio.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records. Mechanism: Angiotensin-converting enzyme inhibitor.
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Releases active oxygen.
- Mechanism
- Releases active oxygen
-
US regulatory status: approved.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records. Mechanism: Probiotic.
- Mechanism
- Probiotic
-
Development asset linked to Chinese Academy of in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor antagonist.
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
blinatumomab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD19.
- Target
- B-lymphocyte antigen CD19
- Mechanism
- T cell surface glycoprotein CD3 cross-linking agent
-
bortezomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
bosentan
Cardiovascular system (C02)US regulatory status: approved. Molecular target: Endothelin receptor, ET-A/ET-B.
- Target
- Endothelin receptor, ET-A/ET-B
- Mechanism
- Endothelin receptor, ET-A/ET-B antagonist
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
brentuximab vedotin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Mechanism: Membrane staining aid in ophthalmic surgery.
- Mechanism
- Membrane staining aid in ophthalmic surgery
-
bromfenac
Sensory organs (S01)Sensory organs (S01) compound in Chinese Academy of's portfolio. Mechanism: Cyclooxygenase inhibitor.
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- D2-like dopamine receptor agonist
-
budesonide
Alimentary tract and metabolism (A07)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Chinese Academy of in public FDA and regional records. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
buprenorphine
Nervous system (N07)US regulatory status: approved. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Kappa opioid receptor agonist
-
US regulatory status: approved. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Kappa opioid receptor partial agonist
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
cabozantinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Mechanism: Hepatocyte growth factor receptor inhibitor.
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
canagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: Aromatic-L-amino-acid decarboxylase.
- Target
- Aromatic-L-amino-acid decarboxylase
- Mechanism
- DOPA decarboxylase inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
carfilzomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
celecoxib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.
- Target
- Prostaglandin G/H synthase 2
- Mechanism
- Cyclooxygenase-2 inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cholecystokinin receptor type A.
- Target
- Cholecystokinin receptor type A
- Mechanism
- Cholecystokinin A receptor agonist
-
cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
Musculo-skeletal system (M09)Musculo-skeletal system (M09) compound in Chinese Academy of's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: Estrogen receptor beta.
- Target
- Estrogen receptor beta
- Mechanism
- Estrogen receptor beta modulator
-
Development asset linked to Chinese Academy of in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
cholic acid
Alimentary tract and metabolism (A05)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Dipeptidase 1.
- Target
- Dipeptidase 1
- Mechanism
- Renal dipeptidase inhibitor
-
cinacalcet
Systemic hormonal preparations (H05)Systemic hormonal preparations (H05) compound in Chinese Academy of's portfolio. Mechanism: Calcium sensing receptor positive allosteric modulator.
- Mechanism
- Calcium sensing receptor positive allosteric modulator
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: Muscle-type nicotinic acetylcholine receptor.
- Target
- Muscle-type nicotinic acetylcholine receptor
- Mechanism
- Muscle-type nicotinic acetylcholine receptor antagonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Chinese Academy of's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
US regulatory status: approved. Molecular target: P2Y purinoceptor 12.
- Target
- P2Y purinoceptor 12
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
colchicine
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Collagen.
- Target
- Collagen
- Mechanism
- Collagen hydrolytic enzyme
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Chinese Academy of's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
crizotinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.
- Target
- ALK tyrosine kinase receptor
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
daclatasvir
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Chinese Academy of's portfolio.
-
US regulatory status: approved. Molecular target: Nonstructural protein 5A.
- Target
- Nonstructural protein 5A
- Mechanism
- Nonstructural protein 5A inhibitor
-
dapagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
daratumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
dasatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- SRC inhibitor
-
daunorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Chinese Academy of's portfolio. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
decitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 1 inhibitor
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
defatted powder of arachis hypogaea l., semen (peanuts)
Various (V01)Various (V01) compound in Chinese Academy of's portfolio. Mechanism: Food allergy desensitisation.
- Mechanism
- Food allergy desensitisation
-
deferasirox
Various (V03)US regulatory status: approved. Molecular target: Iron.
- Target
- Iron
- Mechanism
- Iron chelating agent
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Iron.
- Target
- Iron
- Mechanism
- Iron chelating agent
-
Development asset linked to Chinese Academy of in public FDA and regional records.
-
denosumab
Musculo-skeletal system (M05)US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 11.
- Target
- Tumor necrosis factor ligand superfamily member 11
- Mechanism
- Tumor necrosis factor ligand superfamily member 11 inhibitor
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane disrupting agent
-
Development asset linked to Chinese Academy of in public FDA and regional records.